The ONE Study UK Treg Trial

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

March 23, 2017

Study Completion Date

March 23, 2017

Conditions
End-stage Renal Failure
Interventions
BIOLOGICAL

Autologous regulatory T Cell Product

Autologous regulatory T Cell Product (1-10 million cells/kg) infused intravenously 5 days post renal transplantation. Recipients also receive prednisolone, mycophenolate mofetil, and tacrolimus as detailed in the arm description.

Trial Locations (2)

SE1 9RT

Guy's Hospital, London

OX3 7LE

The Oxford Transplant Centre - Churchill Hospital, Oxford

All Listed Sponsors
collaborator

King's College London

OTHER

lead

Guy's and St Thomas' NHS Foundation Trust

OTHER

NCT02129881 - The ONE Study UK Treg Trial | Biotech Hunter | Biotech Hunter